<abstract xmlns="http://www.w3.org/1999/xhtml"><p> Psoriasis is a common T-cell-mediated autoimmune inflammatory disease. Conventional systemic therapy includes: methotrexate, cyclosporine, retinoids and psoralen ultraviolet A, which are effective, but associated with toxicity and adverse effects which may limit their long-term use. Although effective as well, data on the long-term safety of newly introduced biologic agents are still not available. Herein, we present our clinical experience with rifampicin in the treatment of psoriasis, and review of literature regarding its potential mechanisms of action.</p></abstract>

Psoriasis is a common T-cell-mediated autoimmune inflammatory disease. Conventional systemic therapy includes: methotrexate, cyclosporine, retinoids and psoralen ultraviolet A, which are effective, but associated with toxicity and adverse effects which may limit their long-term use. Although effective as well, data on the long-term safety of newly introduced biologic agents are still not available. Herein, we present our clinical experience with rifampicin in the treatment of psoriasis, and review of literature regarding its potential mechanisms of action.

Alternative treatment of psoriasis - is rifampicin a mild immunosupressor? / Alternativna terapija psorijaze: da li rifampicin ima blago imunosupresivno dejstvo?

Department of Dermatology, Medical Faculty, Sofia Tokuda Hospital, Sofia, Bulgaria

Serbian Journal of Dermatology and Venereology

Psoriasis is a common T-cell-mediated autoimmune inflammatory disease. Conventional systemic therapy includes: methotrexate, cyclosporine, retinoids and...

Alternative treatment of psoriasis - is rifampicin a mild immunosupressor? / Alternativna terapija psorijaze: da li rifampicin ima blago imunosupresivno dejstvo?

Online veröffentlicht: 12. Feb. 2013

Seitenbereich: 5 - 12

DOI: https://doi.org/10.2478/v10249-011-0017-9

This content is open access.